Cargando…

Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients

Multiple myeloma (MM) is an incurable disease with a limited life expectancy of five years from diagnosis. Uncontrolled disease or infections are the main causes of mortality. Daratumumab, a monoclonal antibody against CD38, is approved to treat patients with MM. Its target, CD38, is expressed not o...

Descripción completa

Detalles Bibliográficos
Autores principales: Cottini, Francesca, Huang, Ying, Williams, Nita, Bumma, Naresh, Khan, Abdullah M., Chaudhry, Maria, Devarakonda, Srinivas, Efebera, Yvonne A., Benson, Don M., Rosko, Ashley E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7917249/
https://www.ncbi.nlm.nih.gov/pubmed/33659205
http://dx.doi.org/10.3389/fonc.2020.575168
_version_ 1783657657931923456
author Cottini, Francesca
Huang, Ying
Williams, Nita
Bumma, Naresh
Khan, Abdullah M.
Chaudhry, Maria
Devarakonda, Srinivas
Efebera, Yvonne A.
Benson, Don M.
Rosko, Ashley E.
author_facet Cottini, Francesca
Huang, Ying
Williams, Nita
Bumma, Naresh
Khan, Abdullah M.
Chaudhry, Maria
Devarakonda, Srinivas
Efebera, Yvonne A.
Benson, Don M.
Rosko, Ashley E.
author_sort Cottini, Francesca
collection PubMed
description Multiple myeloma (MM) is an incurable disease with a limited life expectancy of five years from diagnosis. Uncontrolled disease or infections are the main causes of mortality. Daratumumab, a monoclonal antibody against CD38, is approved to treat patients with MM. Its target, CD38, is expressed not only on MM cells but also on common lymphoid precursors and subsets of normal lymphocytes. Daratumumab-induced lymphopenia is common, but its clinical significance is understudied. In this study, we report the baseline characteristics, rates of severe lymphopenia, infections, and clinical trajectory of multiple myeloma patients (n = 100) treated with daratumumab-based regimens at the Ohio State University Comprehensive Cancer Center. We discover high rates of infections, hospital utilization, and severe lymphopenia and identify risks factors for severe lymphopenia, such as low pretreatment absolute lymphocyte count (ALC) values. Severe lymphopenia persists in 23% of patients, resulting in worst survival outcomes. Our data underline the importance of monitoring ALC and consider future use of prophylactic measures or alternative regimens in subsets of MM patients.
format Online
Article
Text
id pubmed-7917249
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-79172492021-03-02 Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients Cottini, Francesca Huang, Ying Williams, Nita Bumma, Naresh Khan, Abdullah M. Chaudhry, Maria Devarakonda, Srinivas Efebera, Yvonne A. Benson, Don M. Rosko, Ashley E. Front Oncol Oncology Multiple myeloma (MM) is an incurable disease with a limited life expectancy of five years from diagnosis. Uncontrolled disease or infections are the main causes of mortality. Daratumumab, a monoclonal antibody against CD38, is approved to treat patients with MM. Its target, CD38, is expressed not only on MM cells but also on common lymphoid precursors and subsets of normal lymphocytes. Daratumumab-induced lymphopenia is common, but its clinical significance is understudied. In this study, we report the baseline characteristics, rates of severe lymphopenia, infections, and clinical trajectory of multiple myeloma patients (n = 100) treated with daratumumab-based regimens at the Ohio State University Comprehensive Cancer Center. We discover high rates of infections, hospital utilization, and severe lymphopenia and identify risks factors for severe lymphopenia, such as low pretreatment absolute lymphocyte count (ALC) values. Severe lymphopenia persists in 23% of patients, resulting in worst survival outcomes. Our data underline the importance of monitoring ALC and consider future use of prophylactic measures or alternative regimens in subsets of MM patients. Frontiers Media S.A. 2021-02-15 /pmc/articles/PMC7917249/ /pubmed/33659205 http://dx.doi.org/10.3389/fonc.2020.575168 Text en Copyright © 2021 Cottini, Huang, Williams, Bumma, Khan, Chaudhry, Devarakonda, Efebera, Benson and Rosko http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Cottini, Francesca
Huang, Ying
Williams, Nita
Bumma, Naresh
Khan, Abdullah M.
Chaudhry, Maria
Devarakonda, Srinivas
Efebera, Yvonne A.
Benson, Don M.
Rosko, Ashley E.
Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients
title Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients
title_full Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients
title_fullStr Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients
title_full_unstemmed Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients
title_short Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients
title_sort real world experience of daratumumab: evaluating lymphopenia and adverse events in multiple myeloma patients
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7917249/
https://www.ncbi.nlm.nih.gov/pubmed/33659205
http://dx.doi.org/10.3389/fonc.2020.575168
work_keys_str_mv AT cottinifrancesca realworldexperienceofdaratumumabevaluatinglymphopeniaandadverseeventsinmultiplemyelomapatients
AT huangying realworldexperienceofdaratumumabevaluatinglymphopeniaandadverseeventsinmultiplemyelomapatients
AT williamsnita realworldexperienceofdaratumumabevaluatinglymphopeniaandadverseeventsinmultiplemyelomapatients
AT bummanaresh realworldexperienceofdaratumumabevaluatinglymphopeniaandadverseeventsinmultiplemyelomapatients
AT khanabdullahm realworldexperienceofdaratumumabevaluatinglymphopeniaandadverseeventsinmultiplemyelomapatients
AT chaudhrymaria realworldexperienceofdaratumumabevaluatinglymphopeniaandadverseeventsinmultiplemyelomapatients
AT devarakondasrinivas realworldexperienceofdaratumumabevaluatinglymphopeniaandadverseeventsinmultiplemyelomapatients
AT efeberayvonnea realworldexperienceofdaratumumabevaluatinglymphopeniaandadverseeventsinmultiplemyelomapatients
AT bensondonm realworldexperienceofdaratumumabevaluatinglymphopeniaandadverseeventsinmultiplemyelomapatients
AT roskoashleye realworldexperienceofdaratumumabevaluatinglymphopeniaandadverseeventsinmultiplemyelomapatients